*After 4 or 6 monthly starting doses, treatment could be every 1-4 months based on your Retina Specialist’s recommendation.
*After 4 or 6 monthly starting doses, treatment could be every 1-4 months based on your Retina Specialist’s recommendation.
Ask your Retina Specialist about VABYSMO.
First and only treatment designed to block both VEGF and Ang-2,† proteins that can lead to leakage and swelling in the eye
Improves vision quickly‡ and maintains vision gains through year 1
After initial starting doses, it's possible to go 1-4 months injection-free.§ See dosing information here.
†Ang-2=angiopoietin-2; VEGF=vascular endothelial growth factor.
‡In clinical trials of 1264 people on VABYSMO and 627 on aflibercept, people gained an average of 6 letters at 1 month for both treatments.
§Approved dosing is 1, 2, 3, or 4 months, and should extend in 1-month increments.
WATCH THE VIDEO TO LEARN MORE
Welcome to VABYSMO.
If you are one of the many people facing the challenges of vision loss... see the possibilities of improved vision with VABYSMO.
VABYSMO is a prescription medicine approved for... the treatment of people with wet age-related macular degeneration—wet AMD... and diabetic macular edema—DME.
Do not receive VABYSMO if you have certain infections, eye swelling or allergic reactions.
With VABYSMO,... you could go 1-4 months between injections... Your Retina Specialist will evaluate your progress to determine the dosing schedule that’s right for you... Imagine the possibilities with VABYSMO.
Please see important information at the end of this video.
VABYSMO works differently from other treatments. Here’s how:
In wet AMD and DME,... there are 2 types of proteins that may lead to blurred vision and possible vision loss.
These proteins can lead to leakage and swelling of blood vessels in the eye.
These 2 proteins are called VEGF and Ang-2.
Other treatments target VEGF.
But VABYSMO is designed to block both types of proteins… to help reduce abnormal blood vessel swelling, help reduce leaking fluid, and help reduce blood vessel growth.
See the possibilities with VABYSMO.
Ask your Retina Specialist if VABYSMO is right for you.
Let’s look at the clinical studies results of VABYSMO in people with wet AMD and DME.
The safety and effectiveness of VABYSMO... were studied for 1 year in 4 clinical trials versus aflibercept.
On average, people with wet AMD gained 6 letters on an eye chart, similar to aflibercept.
Your next wet AMD treatment could be months away. Your Retina Specialist will determine if you can extend your time between injections.
78% of people with wet AMD were able to extend their treatments to every 3 or 4 months. This may not be the experience for all patients.
On average, people with DME gained 11 letters on an eye chart, similar to aflibercept.
VABYSMO gives you a chance to build up to 4 months between injections for DME. Your Retina Specialist can increase or decrease the time between treatments based on their clinical evaluation.
There are 2 possible dosing schedules for people with DME—every 1, 2, 3, or 4 months after 4 starting doses. Or, every 2 months after 6 starting doses.
Talk to your Retina Specialist about a treatment schedule with VABYSMO that’s right for you.
Indications and Important Safety Information
What is VABYSMO?
VABYSMO (faricimab s-v-o-a) is a prescription medicine given by injection into the eye, used to treat adults with Neovascular (Wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).
Do not receive VABYSMO if you:
What is the most important information I should know about VABYSMO?
Before receiving VABYSMO, tell your healthcare provider about all of your medical conditions, including if you:
What should I avoid while receiving VABYSMO?
What are the most common side effects with VABYSMO?
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.
Please see the VABYSMO full Prescribing Information for additional Important Safety Information.
Click the buttons below this video to learn more about how VABYSMO may help you.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.